S. Loukides (Athens, Greece), F. Ricciardolo (Orbassano (TO), Italy)
Collating data from major European population studies – The CADSET (Chronic airway disease early stratification) clinical research collaboration
J. Allinson (London, United Kingdom), S. Afzal (Copenhagen, Denmark), Y. Colak (Copenhagen, Denmark), H. Backman (Luleå, Sweden), M. Van Den Berghe (Groningen, Netherlands), M. Boezen (Groningen, Netherlands), M. Breyer (Vienna, Austria), R. Breyer-Kohansal (Vienna, Austria), O. C. Burghuber (Vienna, Austria), R. Faner (Barcelona, Spain), S. Hartl (Vienna, Austria), D. Jarvis (London, United Kingdom), L. Lahouse (Rotterdam, Netherlands), A. Langhammer (Levanger, Norway), B. Lundback (Gothenburg, Sweden), B. Nwaru (Gothenburg, Sweden), E. Ronmark (Umeå, Sweden), S. Vikjord (Levanger, Norway), J. Vonk (Groningen, Netherlands), S. Vijnant (Ghent, Belgium), V. Szabo (Barcelona, Spain), A. Agusti (Barcelona, Spain), G. Donaldson (London, United Kingdom), J. Wedzicha (London, United Kingdom), J. Vestbo (Manchester, United Kingdom), L. Vanfleteren (Gothenburg, Sweden)
|     |
Measurement of peripheral airspaces by nanoparticles in a group of 618 subjects
J. Löndahl (Lund, Sweden), M. Petersson Sjögren (Lund, Sweden), L. Aaltonen (Lund, Sweden), J. Jakobsson (Lund, Sweden), H. Nicklasson (Lund, Sweden), J. Rissler (Lund, Sweden), P. Wollmer (Lund, Sweden)
| |
Comparison of spirometric markers of severity and reversibility in patients with asthma and/or COPD in NOVELTY
R. Hughes (Cambridge, United Kingdom), R. Del Olmo (Buenos Aires, Argentina), B. Make (Denver, CO, United States of America), D. Price (Aberdeen, United Kingdom), A. Agustí (Barcelona, Spain), E. Rapsomaniki (Cambridge, United Kingdom), H. Müllerová (Cambridge, United Kingdom), J. Vestbo (Manchester, United Kingdom)
| |
Risk Score for Subclinical COPD: The NHLBI Pooled Cohorts Study
S. Bhatt (Birmingham, United States of America), P. Balte (New York, United States of America), J. Schwartz (New York, United States of America), P. Cassano (Ithaca, United States of America), P. Chaves (Miami, United States of America), D. Couper (Chapel Hill, United States of America), D. Jacobs (Minneapolis, United States of America), E. Jerschow (New York, United States of America), R. Kalhan (Chicago, United States of America), R. Kaplan (New York, United States of America), D. Lloyd-Jones (Chicago, United States of America), A. Newman (Pittsburgh, United States of America), G. O'Connor (Boston, United States of America), J. Sanders (Boston, United States of America), B. Smith (Montreal, Canada), J. Umans (Hyattsville, United States of America), W. White (Tougaloo, United States of America), S. Yende (Pittsburgh, United States of America), E. Oelsner (New York, United States of America)
| |
Validation of the codex index in patients with COPD enrolled in randomized clinical trials: A post-hoc analysis of the trilogy, trinity and tribute studies.
P. Almagro (Terrassa, Spain), P. Vaghi (Parma, Italy), S. Tommasini (Verona, Italy), D. González-Segura (Barcelona, Spain), E. Topole (Parma, Italy), G. Georges (Parma, Italy)
| |
Phenotypes, treatable traits, GOLD groups and grades – how they predict mortality risk in COPD patients? (data from the Czech Multicenter Research Database of COPD)
K. Brat (Brno, Czech Republic), V. Koblizek (Hradec Kralove, Czech Republic), M. Svoboda (Brno, Czech Republic), M. Plutinsky (Brno, Czech Republic), J. Zatloukal (Olomouc, Czech Republic), E. Volakova (Olomouc, Czech Republic), B. Novotna (Prague, Czech Republic), P. Popelkova (Ostrava, Czech Republic), T. Dvorak (Mlada Boleslav, Czech Republic), O. Kudela (Hradec Kralove, Czech Republic), M. Kopecky (Hradec Kralove, Czech Republic), P. Musilova (Jihlava, Czech Republic), E. Kocova (Hradec Kralove, Czech Republic), P. Vanik (Ceska Budejovice, Czech Republic), L. Heribanova (Prague, Czech Republic)
| |